Phospho-BRD4

transcription plasticity and drug targeting

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

BRD4 is an epigenetic regulator and transcription cofactor whose phosphorylation by CK2 and dephosphorylation by PP2A modulates its function in chromatin targeting, factor recruitment, and cancer progression. While the bromodomains of BET family proteins, including BRD4, BRD2, BRD3 and BRDT, have been the primary targets of small compounds such as JQ1, I-BET and MS417 that show promising anticancer effects against some hematopoietic cancer and solid tumors, drug resistance upon prolonged treatment necessitates a better understanding of alternative pathways underlying not only the resistance but also persistent BET protein dependence for identifying new targets and effective combination therapy strategies.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalDrug Discovery Today: Technologies
Volume19
DOIs
StatePublished - Mar 1 2016

Fingerprint

Drug Delivery Systems
Neoplasms
Drug Resistance
Epigenomics
Chromatin
Proteins
Phosphorylation
Therapeutics

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Drug Discovery

Cite this

Phospho-BRD4 : transcription plasticity and drug targeting. / Chiang, Cheng Ming.

In: Drug Discovery Today: Technologies, Vol. 19, 01.03.2016, p. 17-22.

Research output: Contribution to journalReview article

@article{9675d48213bb4f9683d53cf1704d5263,
title = "Phospho-BRD4: transcription plasticity and drug targeting",
abstract = "BRD4 is an epigenetic regulator and transcription cofactor whose phosphorylation by CK2 and dephosphorylation by PP2A modulates its function in chromatin targeting, factor recruitment, and cancer progression. While the bromodomains of BET family proteins, including BRD4, BRD2, BRD3 and BRDT, have been the primary targets of small compounds such as JQ1, I-BET and MS417 that show promising anticancer effects against some hematopoietic cancer and solid tumors, drug resistance upon prolonged treatment necessitates a better understanding of alternative pathways underlying not only the resistance but also persistent BET protein dependence for identifying new targets and effective combination therapy strategies.",
author = "Chiang, {Cheng Ming}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.ddtec.2016.05.003",
language = "English (US)",
volume = "19",
pages = "17--22",
journal = "Drug Discovery Today: Technologies",
issn = "1740-6749",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Phospho-BRD4

T2 - transcription plasticity and drug targeting

AU - Chiang, Cheng Ming

PY - 2016/3/1

Y1 - 2016/3/1

N2 - BRD4 is an epigenetic regulator and transcription cofactor whose phosphorylation by CK2 and dephosphorylation by PP2A modulates its function in chromatin targeting, factor recruitment, and cancer progression. While the bromodomains of BET family proteins, including BRD4, BRD2, BRD3 and BRDT, have been the primary targets of small compounds such as JQ1, I-BET and MS417 that show promising anticancer effects against some hematopoietic cancer and solid tumors, drug resistance upon prolonged treatment necessitates a better understanding of alternative pathways underlying not only the resistance but also persistent BET protein dependence for identifying new targets and effective combination therapy strategies.

AB - BRD4 is an epigenetic regulator and transcription cofactor whose phosphorylation by CK2 and dephosphorylation by PP2A modulates its function in chromatin targeting, factor recruitment, and cancer progression. While the bromodomains of BET family proteins, including BRD4, BRD2, BRD3 and BRDT, have been the primary targets of small compounds such as JQ1, I-BET and MS417 that show promising anticancer effects against some hematopoietic cancer and solid tumors, drug resistance upon prolonged treatment necessitates a better understanding of alternative pathways underlying not only the resistance but also persistent BET protein dependence for identifying new targets and effective combination therapy strategies.

UR - http://www.scopus.com/inward/record.url?scp=84992392031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992392031&partnerID=8YFLogxK

U2 - 10.1016/j.ddtec.2016.05.003

DO - 10.1016/j.ddtec.2016.05.003

M3 - Review article

VL - 19

SP - 17

EP - 22

JO - Drug Discovery Today: Technologies

JF - Drug Discovery Today: Technologies

SN - 1740-6749

ER -